Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pfizer (PFE – Research Report) and Oneview Healthcare Chess Depository Interests repr 1 (ONVVF – Research Report).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pfizer (PFE)
In a report released yesterday, Justin Smith from Bernstein maintained a Hold rating on Pfizer, with a price target of $30.00. The company’s shares closed last Friday at $24.79, close to its 52-week low of $24.48.
According to TipRanks.com, Smith is ranked #3539 out of 9922 analysts.
Pfizer has an analyst consensus of Moderate Buy, with a price target consensus of $28.40, which is a 13.7% upside from current levels. In a report issued on July 22, TR | OpenAI – 4o also downgraded the stock to Hold with a $26.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Oneview Healthcare Chess Depository Interests repr 1 (ONVVF)
In a report released yesterday, Martyn Jacobs from Bell Potter maintained a Buy rating on Oneview Healthcare Chess Depository Interests repr 1, with a price target of A$0.34. The company’s shares closed last Friday at $0.16, equals to its 52-week high of $0.16.
According to TipRanks.com, Jacobs is ranked #9692 out of 9922 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Oneview Healthcare Chess Depository Interests repr 1 with a $0.23 average price target.
Read More on PFE:
- Pfizer’s Hold Rating: Navigating Competitive Pressures and Uncertain Growth Prospects
- Pfizer’s New Vaccine Study: A Potential Game Changer in China
- Pfizer’s Uncertain Growth Prospects and Revenue Stability Prompt Hold Rating
- Pfizer, BioNTech get CHMP opinion for COVID-19 vaccine marketing authorization
- Pfizer’s New Phase 1 Study: A Potential Game-Changer?